Pcp prophylaxis steroid therapy

Discontinuation of one of multiple strong CYP3A4 inducers may not require additional dose adjustment. Assess the everolimus trough level 2 weeks after discontinuation of one of multiple strong CYP3A4 inducers. If all potent inducers are discontinued, consider a washout period of at least 3 to 5 days (reasonable time for significant enzyme de-induction) before the Votubia dose is returned to the dose used prior to initiation of the co-administration. The everolimus trough concentrations should be assessed 2 to 4 weeks later since the natural degradation time of the induced enzymes has to be taken into account (see sections and ).

Stomatitis is the most commonly reported adverse reaction in patients treated with Afinitor (see sections and ). In a post-marketing single-arm study in postmenopausal women with advanced breast cancer (N=92), topical treatment with dexamethasone mg/5 ml alcohol-free oral solution was administered as a mouthwash (4 times daily for the initial 8 weeks of treatment) to patients at the time of initiating treatment with Afinitor (10 mg/day) plus exemestane (25 mg/day) to reduce the incidence and severity of stomatitis. The incidence of Grade ≥2 stomatitis at 8 weeks was % (n=2/85 evaluable patients) which was lower than historically reported. The incidence of Grade 1 stomatitis was % (n=16/85) and no cases of Grade 3 or 4 stomatitis were reported. The overall safety profile in this study was consistent with that established for everolimus in the oncology and tuberous sclerosis complex (TSC) settings, with the exception of a slightly increased frequency of oral candidiasis which was reported in % (n=2/92) of patients.

Pcp prophylaxis steroid therapy

pcp prophylaxis steroid therapy


pcp prophylaxis steroid therapypcp prophylaxis steroid therapypcp prophylaxis steroid therapypcp prophylaxis steroid therapypcp prophylaxis steroid therapy